PLUVICTO

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms
  The FDA has denied ITM Isotopes Technologies’ lead pipeline candidate for a rare group of tumors due to qualms over the drug’s manufacturing.
  fiercebiotech · 5d ago
• J&J pharma leader to retire; Krystal slumps on gene therapy miss
  Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.
  biopharma_dive · 10d ago
• FDA expands Pluvicto label, making it available to most metastatic prostate cancer patients
  The FDA approved Novartis’ radiopharma drug Pluvicto for use alongside hormone therapy, making the drug available to many more patients. The approval nearly doubles the eligible patient population…
  endpoints · 11d ago
• Curium strikes up to $8B deal for radiopharma rival Lantheus
  Months after reports first linked Curium to a potential Lantheus takeover, the radiopharma players have made it official with a deal worth up to $8 billion.
  fiercebiotech · 11d ago
• Recon: AstraZeneca, BMS discuss merger; FDA broadens indication for Novartis’ Pluvicto
  Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
  raps · 12d ago
• Novartis scraps mid-stage radiopharma asset as Pluvicto soars
  The discontinued asset, being trialed for breast cancer and solid tumors, had yielded disappointing data, leading to Novartis’ decision to abandon development, according to a company spokesperson.
  biospace · 24d ago
• Novartis climbs on upbeat drug sales as key readouts loom
  A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.
  biopharma_dive · 24d ago
• Novartis stays 'geography-agnostic' in dealmaking amid flurry of China deals
  Novartis will continue to be on the lookout for bolt-on deals below $2 billion, CEO Vas Narasimhan said Tuesday on the pharma's second quarter earnings call—though major pickups aren’t completely o…
  biospace · 24d ago
• Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’
  Novartis has dropped a phase 2-stage radioligand therapy after the candidate disappointed in the clinic.
  fiercebiotech · 25d ago
• Radiopharma maker AdvanCell hauls in $315M for Pluvicto challenger
  AdvanCell raised a $315 million Series D to study a lead-based prostate cancer agent and shore up its US manufacturing of the radioactive treatment. The round marks one of the largest yet for a rad…
  endpoints · 1mo ago